ETF Building Blocks Content Hub Will the Biotech Space Consolidate in the Back Half of the Year? By Tom LydonJuly 14, 2021
ETF Building Blocks Content Hub Post-Pandemic Healthcare Could Feature More Biotech M&A By Tom LydonJune 10, 2021
ETF Building Blocks Content Hub As Biotech Consolidation Heats up, ‘SBIO’ Could Be a Winner By Tom LydonMay 24, 2021
ETF Building Blocks Content Hub ALPS ‘SBIO’ ETF: Trial Progress Meets Investing Success By Tom LydonJanuary 25, 2021
ETF Building Blocks Content Hub Don’t Miss Out on Rampant Biotech Mergers with the SBIO ETF By Tom LydonJanuary 13, 2021
Innovative ETFs Content Hub Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021 By Max ChenDecember 31, 2020
ETF Building Blocks Content Hub How Increased FDA Activity Can Benefit ETFs in Your Portfolio By Tom LydonNovember 19, 2020
ETF Building Blocks Content Hub More than Just COVID: Hot ETFs for Medical Breakthroughs By Tom LydonNovember 5, 2020
ETF Building Blocks Content Hub Post-Election Considerations for a Nifty Biotech ETF By Tom LydonOctober 7, 2020
ETF Building Blocks Content Hub Betting on Biotech With Utility Beyond Covid-19 By Tom LydonJuly 31, 2020
ETF Building Blocks Content Hub A Healthcare ETF Could Benefit From Index Reshuffling By Tom LydonJune 23, 2020
ETF Building Blocks Content Hub Biotech ETF Doesn’t Need Coronavirus Vaccines to Soar By Tom LydonJune 2, 2020
Disruptive Technology Content Hub Biotech ETFs Are Not Riding the Wave from Coronavirus Panic By Max ChenJanuary 24, 2020
